Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
ATF3 (activating transcription factor 3) plays an important role in regulating cell proliferation, apoptosis, inflammation, immune homeostasis, and differentiation of organs and tissues. For example, in patients with prostate cancer, ATF3 accelerates tumor cell apoptosis to achieve anticancer effects. Previous studies have shown that ATF3 is a fast-response gene in the early stage of stress and is stably expressed at low levels in cells under normal conditions. However, certain stimuli such as reactive oxygen species, ultraviolet stimuli, myocardial ischemia, hypoxic state, and even the use of certain drugs such as insulin, doxorubicin, etc., can increase their transient expression, especially in myocardial tissue.
During the embryonic period, there is a large amount of BMP10 in the blood circulation, which belongs to one of the TGF-β superfamily members and is critical for cardiac development, especially myocardial tissue. Some researchers have hypothesized that there is a BMP10/ATF3 signaling pathway in myocardial tissue (this signaling pathway is important in regulating immune responses and cardiovascular development). There is an ATF/CREB binding domain regulated by the Smad1 to Smad4 molecule in the TGF-β/BMP10 reaction domain. By continuously detecting the BMP10 concentration and ATF3 expression levels in the blood circulation of the embryo during and after the embryo, they found that their concentrations gradually increased with the development of the heart. And in the BMP10 gene overexpressing mice, the ATF3 content was significantly increased. Therefore, ATF3 is considered to be an important gene highly related to cardiovascular development.
ATF3's Auto-Inhibition Loop
According to Koivisto et al, ATF3 is a stress-inducible gene that is widely expressed in rat myocardial tissue under pressure-induced induction and involves multiple signaling pathways such as MAPK, NF-κB, JNK, and cAMP-PKA. The study found that ATF3 expression is activated by a variety of stress signals, and its expression in myocardial tissue is often abnormally elevated.
Under the conditions of endothelin-1 (ET-1) stimulation, the MAPK signaling pathway is activated in the heart, which gradually leads to cardiac hypertrophy and ventricular remodeling. At the same time, ATF3 is effectively induced, which protects the heart by inhibiting the expression of various hypertrophy molecules. In the body, the expression of ATF3 is regulated by various factors, such as various signal molecules, growth factors, and microRNAs. However, in recent years, Tindall et al. proposed that there is an autorepression loop in ATF3, that is, there is an auto-feedback system in ATF3.
Figure 1. Signal transduction pathway of ATF3 protecting MIRI via TLR-4/NF-κB-mediated inflammation. (Yang, et al. 2015).
Previous studies have demonstrated that ATF3 may inhibit its expression by binding to the TATA box of its downstream target promoter, however, it is difficult to detect its expression status in an endogenous system. Tindall examined the relationship between ATF3 mRNA expression and protein expression in myocardial tissue. The results showed that the ATF3 gene gradually increased after ET-1 stimulation, and then gradually decreased after reaching the peak at 30 min and decreased to baseline at 4 h. However, the expression curve of its protein is relatively delayed, so he speculated that the protein product of ATF3 can inhibit its mRNA expression. Tindall later confirmed this hypothesis through experimental methods of mathematical modeling, in which ATF3 has an autoinhibitory loop to regulate the expression of its own genes.
ATF3 and Cardiovascular Disease
Brooks et al. used ATF3 knockout mice and wild mice as subjects to calculate myocardial infarct size by simulated ischemia-reperfusion model and RT-PCR and Western blot. The results showed that in the case of cardiac ATF3 knockout, the infarct size of myocardial tissue increased significantly, and inflammatory factors and adhesion molecules such as IL-6, IL-12β, ICAM1, etc. increased significantly. The results indicate that ATF3 has a protective effect on the heart during ischemia.
Cardiac hypertrophy is a chronic adaptive compensatory mechanism of stress and volume overload in the heart. It is a complex pathophysiological process mediated by various neurohumoral factors. Studies have shown that ATF3 knockout can aggravate stress-induced cardiac hypertrophy and myocardial fibrosis, further impairing cardiac function. On the other hand, ATF3 can inhibit MAPK, JNK, PI3K-AKT and other signaling pathways to weaken the development of cardiac hypertrophy. The above studies confirm that ATF3 is an effective protective gene for cardiac hypertrophy. However, Koren et al. believe that the expression of ATF3 in the heart can promote the rise of blood pressure and the occurrence and development of cardiac hypertrophy, causing deterioration of cardiac function, contrary to the above viewpoint.
Heart failure is the end stage of various cardiovascular diseases, accompanied by the production of autophagy in the development of heart failure. Autophagy is divided into three methods: macroautophagy, microautophagy, and chaperone-mediated autophagy. Lin et al. used ATF3 knockout mice and WT mice as subjects to induce heart failure by transverse aortic banding (TAB). The results of echocardiography and Western blot showed that the cardiac function of the ATF3 knockout group was significantly worse and the expression of c-caspase-3 was increased. Tert-butyl hydroquinone (tBHQ) is a drug that promotes ATF3 expression. After over-expression of ATF3 in mouse hearts by transfection of ATF3 with adenovirus or intravenous injection of tBHQ, the above situation was significantly reversed. These results suggest that the absence of ATF3 can aggravate stress-induced heart failure.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.